메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Herbalgy, Pain Management Expert, Harnesses the Wisdom of Traditional Chinese Medicine to Safeguard Hong Kong's Health, Proudly Appoints Moses Chan as Brand Ambassador

Download high-resolution images: https://cutt.ly/IrGBefFJ HONG KONG, Aug. 18, 2025 -- As Hong Kong's pain management expert, Herbalgy has been serving the community since its founding in 1999. For over 25 years, the brand has been dedicated to promoting healthy living and pain management, with a steadfast commitment to product innovation. By integrating the wisdom of Traditional Chinese Medicine (TCM) into modern life, Herbalgy has become a trusted name among Hong Kong people. Shared Values, Shared Mission Herbalgy has officially appointed Moses Chan — one
- 김갑성 기자
- 2025-08-18 10:00
New support group to provide social and community support for neurofibromatosis patients

[ 메디채널 김갑성 기자 ] Co-founded by individuals living with this rare genetic condition, the Neurofibromatosis Society Singapore seeks to close gaps in mental and emotional care SINGAPORE, Aug. 18, 2025 -- A new patient-led support group, the Neurofibromatosis Society (NFS) Singapore, has been recently registered with the Registry of Societies to provide emotional, psychosocial, and financial support for people affected by neurofibromatosis (NF) – a rare genetic condition that causes the development of tumours affecting nerves on the skin, brain, spinal cord and other parts of the body.&n
- 김갑성 기자
- 2025-08-18 09:00
Ascletis Announces the Combination of ASC47 and ASC31, its Dual GLP-1R/GIPR Peptide Agonist, Demonstrated Significantly Greater Weight Loss Compared to the Combination of ASC47 and Tirzepatide in an Animal Model of Obesity

- Combination of a low dose of ASC47 with ASC31, a novel peptide agonist targeting both GLP-1 receptor (GLP-1R) and GIP receptor (GIPR), resulted in a 44.8% reduction in body weight after 14 days of treatment in a diet-induced obese (DIO) mouse model. - Combination of a low dose of ASC47 with ASC31 demonstrated statistically significantly greater efficacy than a combination of a low dose of ASC47 with tirzepatide, 44.8% compared to 38.1%, respectively, in the DIO mouse model. HONG KONG, Aug. 18, 2025 -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces encouragi
- 김갑성 기자
- 2025-08-18 08:15
GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation

[ 메디채널 김갑성 기자 ] Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation PISCATAWAY, N.J., Aug. 17, 2025 -- GenScript Biotech Corporation (HK.1548), a global pioneer in life sciences innovation, today announced outstanding interim results for the first half of 2025, underscoring its ability to deliver profitable growth at scale through strategic globalization, differentiated technology, and relentless innovation. Fueled by robust demand across all business segments and expansion into key international markets, GenScript achie
- 김갑성 기자
- 2025-08-17 20:01
VARON's Lung Health Awareness Initiative Urges Proactive Steps for Allergy and Flu this Fall Season

NEW YORK, Aug. 15, 2025 -- With allergy and flu season approaching, VARON is calling on individuals to take preventive measures to protect their lungs. Through its "Every Breath Counts" initiative, the oxygen concentrator manufacturer is partnering with respiratory health experts to share practical lung care strategies and introduce tools — from at home oxygen concentrators to lightweight portable oxygen concentrators — to help people maintain optimal oxygen levels during seasonal flare-ups. As part of its Every Breath Counts initiative, VARON recently h
- 김갑성 기자
- 2025-08-15 23:08
BestQool Announces Summer Promotion and Fall Refresh with New Logo and BQ60Pro Preview

[ 메디채널 김갑성 기자 ] Summer Appreciation Sales Offers 12% Off All Products NEW YORK, Aug. 15, 2025 -- BestQool , a pioneer manufacturer of home-use red light therapy devices, is excited to unveil its latest breakthrough product – the BQ60Pro. Based on years of experience and customer feedback, this small yet powerful home-use device now provides six wavelengths for maximum therapeutic protocols, high power output, and a versatile mounting system that completely redefines flexibility in home light therapy. Ahead of the Fall release, BestQool will be holding its Summer Appre
- 김갑성 기자
- 2025-08-15 21:00
Tie "James" Li, Chairman of NMHI, To Speak at XRP Seoul 2025 Global Conference

ONTARIO, Calif., Aug. 15, 2025 -- Tie "James" Li, Chairman and CEO of Nature's Miracle Holding Inc. (OTCQB:NMHI) will attend the XRP Seoul 2025 Global Conference as a keynote speaker on September 21, 2025. XRP SEOUL 2025 hosted by XRPL Korea is a global conference bringing together XRP holders, developers, and ecosystem projects from around the world. Taking place on September 21, 2025, the event features sessions on market outlooks, Web3 go-to-market strategies, and the evolving regulatory landscape. There will be over 3,000 attendees and over 100 compa
- 황정호 기자
- 2025-08-15 20:30
Novel Gene Therapy for ALS cleared for global trials in China and the U.S.

BEIJING, Aug. 15, 2025 -- SineuGene Therapeutics Co., Ltd. ("SineuGene"), clinical-stage biotechnology company that mainly focuses on gene therapies for neurological disorders, announced today that China's National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for SNUG01, a groundbreaking gene therapy product for amyotrophic lateral sclerosis (ALS). This milestone follows a prior clearance of SNUG01's IND application by the U.S. Food and Drug Administration (FDA) in March 2025, paving the way for the initiation of a Phase I/IIa mul
- 김갑성 기자
- 2025-08-15 19:00
Saigon Technology Drives Industry-Specific AI Transformation, Moving Businesses Beyond SaaS Limitations

[ 메디채널 김갑성 기자 ] Vietnamese software leader leverages AI and domain expertise to help industries modernize workflows and reduce long-term tech costs. HO CHI MINH CITY, Vietnam, Aug. 15, 2025 -- As global businesses outgrow generic SaaS tools, Saigon Technology is delivering next-gen, AI-powered custom software for healthcare, fintech, logistics, and e-commerce — unlocking productivity and digital resilience. According to a 2024 report by Vietnam's Ministry of Science and Technology, digital adoption among local businesses surged from 30% in 2021 to nearly 70% in 2024. Many of t
- 김갑성 기자
- 2025-08-15 10:00
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC

Shanghai, Aug. 15, 2025 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that etrasimod (VELSIPITY®) has been included in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults (the "Updated Guidelines"). In patients with moderately to severely active ulcerative colitis (UC), the updated guidelines recommend S1P receptor modulators, including etrasimod, are recommended for induct
- 김갑성 기자
- 2025-08-15 09:35

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-09-05_FRI

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 05일 13시 00분